Abstract
8517Background: Thymic epithelial tumors are rare and thymic carcinomas represent about 10% of them and have most aggressive behavior. There are few treatment options for thymic carcinoma after failing chemotherapy. Unlike thymomas, thymic carcinomas are usually not associated with autoimmune disorders. Strong PD-L1 expression has been reported in thymic epithelial tumors. We are conducting a phase II study of pembrolizumab in patients with thymic carcinomas. Methods: Main eligibility criteria include: progression after at least one line of chemotherapy, ECOG performance status of 0-2, no history of autoimmune disease or other malignancy requiring treatment, and adequate organ function. Pembrolizumab is given at 200mg every 3 weeks. Primary objective of the study is response rate by RECIST v1.1 criteria; secondary objectives are PFS and OS, and tolerability. Results: From March 2015 the study has accrued 23 patients. 16 were male, 19 Caucasians, median age was 58 (35-75), 9 had squamous carcinoma histolog...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
